Suppr超能文献

大流行期间马托格罗索州预防 COVID-19 使用伊维菌素的流行率:基于家庭的横断面研究。

Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study.

机构信息

Universidade Federal de Mato Grosso, Institute for Collective Health - Cuiabá (MT), Brazil.

Universidade do Estado de Mato Grosso - Tangará da Serra (MT), Brazil.

出版信息

Rev Bras Epidemiol. 2023 May 8;26:e230026. doi: 10.1590/1980-549720230026. eCollection 2023.

Abstract

OBJECTIVE

To analyze the use of ivermectin as COVID-19 prevention method by the population of Mato Grosso in 2020.

METHODS

This is a home-based survey, carried out between September and October 2020, in 10 pole cities of the socioeconomic regions of State. The use of ivermectin was evaluated through the question: "Did you take ivermectin to prevent COVID-19?". Sociodemographic variables (sex, age group, education, family income), current work situation, being benefitted by government financial programs, as well as symptoms, seroprevalence of antibodies against SARS-CoV-2, and previous diagnosis of COVID-19 were evaluated. Prevalence and their associations were estimated using the chi-square test.

RESULTS

4.206 individuals were evaluated for prevalence of ivermectin use; 58.3% of the individuals responded positively, this rate being higher in the municipalities of the western region of the state (66.6%). There was no significant difference between sexes, but the prevalence was higher among people aged 50-59 years (69.7%), who were white (66.5%), with complete higher education or more (68.8%) and higher family income (≥3 minimum wages-64.2%). The use of this drug was even higher among participants who considered their knowledge of the disease good or very good (65.0%), who reported having symptoms of COVID-19 (75.3%), and who had been previously diagnosed with the disease (91.2%).

CONCLUSION

There was a high prevalence of use of ivermectin as a method to prevent covid-19 by the population of Mato Grosso, indicating the need for strategies to inform the population about the risks of off-label use of drugs and to combat the advertising of drugs that are ineffective against COVID-19.

摘要

目的

分析 2020 年马托格罗索州居民将伊维菌素用作 COVID-19 预防方法的情况。

方法

这是一项基于家庭的调查,于 2020 年 9 月至 10 月在该州社会经济区域的 10 个首府城市进行。通过以下问题评估伊维菌素的使用情况:“您是否服用伊维菌素预防 COVID-19?”。评估了社会人口学变量(性别、年龄组、教育程度、家庭收入)、当前工作状况、是否受益于政府财政计划,以及症状、针对 SARS-CoV-2 的抗体血清阳性率和之前的 COVID-19 诊断情况。使用卡方检验估计了患病率及其关联。

结果

对 4206 名个体进行了伊维菌素使用的患病率评估;58.3%的个体回答为阳性,该州西部地区的市镇这一比例更高(66.6%)。性别之间无显著差异,但 50-59 岁人群的患病率更高(69.7%),他们是白人(66.5%),具有完整的高等教育或以上(68.8%)和更高的家庭收入(≥3 最低工资-64.2%)。认为自己对疾病的了解良好或非常好的参与者(65.0%)、报告有 COVID-19 症状的参与者(75.3%)和以前被诊断出患有该疾病的参与者(91.2%)使用这种药物的比例更高。

结论

马托格罗索州居民将伊维菌素作为预防 COVID-19 的方法的使用率很高,这表明有必要制定策略,向公众宣传药物标签外使用的风险,并打击宣传对 COVID-19 无效的药物。

相似文献

1
Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study.
Rev Bras Epidemiol. 2023 May 8;26:e230026. doi: 10.1590/1980-549720230026. eCollection 2023.
2
[Prevalence of SARS-CoV-2 antibodies in the State of Mato Grosso, Brazil: a population-based survey].
Cad Saude Publica. 2022 Jun 8;38(5):e00093021. doi: 10.1590/0102-311XPT093021. eCollection 2022.
6
Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
JAMA Netw Open. 2021 Nov 1;4(11):e2132923. doi: 10.1001/jamanetworkopen.2021.32923.
7
Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
Braz J Infect Dis. 2021 Jul-Aug;25(4):101604. doi: 10.1016/j.bjid.2021.101604. Epub 2021 Aug 10.
9
COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil.
J Appl Oral Sci. 2022 Oct 3;30:e20220016. doi: 10.1590/1678-7757-2022-0016. eCollection 2022.

本文引用的文献

2
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662.
3
[Prevalence of SARS-CoV-2 antibodies in the State of Mato Grosso, Brazil: a population-based survey].
Cad Saude Publica. 2022 Jun 8;38(5):e00093021. doi: 10.1590/0102-311XPT093021. eCollection 2022.
6
The regrettable story of the "Covid Kit" and the "Early Treatment of Covid-19" in Brazil.
Lancet Reg Health Am. 2021 Dec;4:100089. doi: 10.1016/j.lana.2021.100089. Epub 2021 Oct 1.
7
The infodemic transcends the pandemic.
Cien Saude Colet. 2021 Sep;26(9):4065-4068. doi: 10.1590/1413-81232021269.12822021. Epub 2021 Jul 2.
8
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
J Infect Chemother. 2021 Dec;27(12):1743-1749. doi: 10.1016/j.jiac.2021.08.021. Epub 2021 Aug 25.
10
Ivermectin for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验